{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:07:01Z","timestamp":1791922021144,"version":"4.3.4"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T00:00:00Z","timestamp":1617148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T00:00:00Z","timestamp":1617148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s00467-021-05052-5","type":"journal-article","created":{"date-parts":[[2021,3,30]],"date-time":"2021-03-30T23:09:55Z","timestamp":1617145795000},"page":"2759-2767","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Oral cyclophosphamide therapy in 100 children with steroid-sensitive nephrotic syndrome: experience from a developing country"],"prefix":"10.1007","volume":"36","author":[{"given":"Jasjeet","family":"Sandhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak","family":"Bhat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4033-8693","authenticated-orcid":false,"given":"Gurdeep Singh","family":"Dhooria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Puneet A.","family":"Pooni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddharth","family":"Bhargava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shruti","family":"Kakkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karambir S.","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,31]]},"reference":[{"key":"5052_CR1","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1093\/ndt\/gfq405","volume":"26","author":"B Cammas","year":"2011","unstructured":"Cammas B, Harambat J, Bertholet-Thomas A, Bouissou F, Morin D, Guigonis V, Bendeddouche S, Afroukh-Hacini N, Cochat P, Llanas B, Decramer S, Ranchin B (2011) Long-term effects of cyclophosphamide therapy in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome. Nephrol Dial Transplant 26:178\u2013184. https:\/\/doi.org\/10.1093\/ndt\/gfq405","journal-title":"Nephrol Dial Transplant"},{"key":"5052_CR2","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1007\/s10157-015-1216-x","volume":"20","author":"S Nishi","year":"2016","unstructured":"Nishi S, Ubara Y, Utsunomiya Y, Okada K, Obata Y, Kai H, Kiyomoto H, Goto S, Konta T, Sasatomi Y, Sato Y, Nishino T, Tsuruya K, Furuichi K, Hoshino J, Watanabe Y, Kimura K, Matsuo S (2016) Evidence-based clinical practice guidelines for nephrotic syndrome 2014. Clin Exp Nephrol 20:342\u2013370. https:\/\/doi.org\/10.1007\/s10157-015-1216-x","journal-title":"Clin Exp Nephrol"},{"key":"5052_CR3","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1590\/s0100-879x2004000900011","volume":"37","author":"R Martinelli","year":"2004","unstructured":"Martinelli R, Pereira L, Silva O, Okumura A, Rocha H (2004) Cyclophosphamide in the treatment of focal segmental glomerulosclerosis. Braz J Med Biol Res 37:1365\u20131372. https:\/\/doi.org\/10.1590\/s0100-879x2004000900011","journal-title":"Braz J Med Biol Res"},{"key":"5052_CR4","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/BF00442686","volume":"147","author":"I Shohet","year":"1988","unstructured":"Shohet I, Meyerovitch J, Aladiem M, Boichis H (1988) Cyclophosphamide in treatment of minimal change nephrotic syndrome. Eur J Pediatr 147:239\u2013241. https:\/\/doi.org\/10.1007\/BF00442686","journal-title":"Eur J Pediatr"},{"key":"5052_CR5","first-page":"1326","volume":"8","author":"C Ponticelli","year":"1993","unstructured":"Ponticelli C, Edefonti A, Ghio L, Rizzoni G, Rinaldi S, Gusmano R, Lama G, Zacchello G, Confalonieri R, Altieri P, Bettinelli A, Maschio G, Cinotti GA, Fuiano G, Schena FP, Castellani A, Delia Casa-Alberighi O (1993) Cyclosporin versus cyclophosphamide for patients with steroid-dependent and frequently relapsing idiopathic nephrotic syndrome: a multicentre randomized controlled trial. Nephrol Dial Transplant 8:1326\u20131332","journal-title":"Nephrol Dial Transplant"},{"key":"5052_CR6","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1007\/s00467-008-0771-8","volume":"23","author":"V S\u00fcmegi","year":"2008","unstructured":"S\u00fcmegi V, Haszon I, Bereczki C, Papp F, T\u00fari S (2008) Long-term follow-up after cyclophosphamide and cyclosporine-A therapy in steroid-dependent and resistant nephrotic syndrome. Pediatr Nephrol 23:1085\u20131092. https:\/\/doi.org\/10.1007\/s00467-008-0771-8","journal-title":"Pediatr Nephrol"},{"key":"5052_CR7","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/ki.1981.39","volume":"19","author":"N Siegel","year":"1981","unstructured":"Siegel N, Gaudio K, Krassner L, McDonald B, Anderson F, Kashgarian M (1981) Steroid-dependent nephrotic syndrome in children: histopathology and relapses after cyclophosphamide treatment. Kidney Int 19:454\u2013459","journal-title":"Kidney Int"},{"key":"5052_CR8","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1136\/bmj.1.5645.666","volume":"1","author":"MW Moncrieff","year":"1969","unstructured":"Moncrieff MW, White RH, Oggs CS, Cameron JS (1969) Cyclophosphamide therapy in the nephrotic syndrome in childhood. Br Med J 1:666\u2013671. https:\/\/doi.org\/10.1136\/bmj.1.5645.666","journal-title":"Br Med J"},{"key":"5052_CR9","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1159\/000183575","volume":"41","author":"A Tejani","year":"1985","unstructured":"Tejani A, Phadke K, Nicastri A, Adamson O, Chen CK, Trachtman H, Tejani C (1985) Efficacy of cyclophosphamide in steroid-sensitive childhood nephrotic syndrome with different morphological lesions. Nephron 41:170\u2013173. https:\/\/doi.org\/10.1159\/000183575","journal-title":"Nephron"},{"key":"5052_CR10","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.autrev.2018.04.007","volume":"17","author":"C Ponticelli","year":"2018","unstructured":"Ponticelli C, Escoli R, Moroni G (2018) Does cyclophosphamide still play a role in glomerular diseases? Autoimmun Rev 17:1022\u20131027. https:\/\/doi.org\/10.1016\/j.autrev.2018.04.007","journal-title":"Autoimmun Rev"},{"key":"5052_CR11","doi-asserted-by":"publisher","first-page":"965","DOI":"10.4103\/1319-2442.100877","volume":"23","author":"AA Al Salloum","year":"2012","unstructured":"Al Salloum AA, Muthanna A, Bassrawi R, Al Shehab AA, Al Ibrahim A, Islam MZ, Al Hasan K (2012) Long-term outcome of the difficult nephrotic syndrome in children. Saudi J Kidney Dis Transpl 23:965\u2013972. https:\/\/doi.org\/10.4103\/1319-2442.100877","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"5052_CR12","first-page":"203","volume":"45","author":"A Bagga","year":"2008","unstructured":"Indian Pediatric Nephrology Group, Indian Academy of Pediatrics, Bagga A, Ali U, Banerjee S, Kanitkar M, Phadke KD, Senguttuvan P, Sethi S, Shah M (2008) Management of steroid sensitive nephrotic syndrome: revised guidelines. Indian Pediatr 45:203\u2013214","journal-title":"Indian Pediatr"},{"key":"5052_CR13","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1007\/s00467-011-1830-0","volume":"26","author":"S Azib","year":"2011","unstructured":"Azib S, Macher MA, Kwon T, Dechartres A, Alberti C, Loirat C, Desch\u00eanes G, Baudouin V (2011) Cyclophosphamide in steroid-dependent nephrotic syndrome. Pediatr Nephrol 26:927\u2013932. https:\/\/doi.org\/10.1007\/s00467-011-1830-0","journal-title":"Pediatr Nephrol"},{"key":"5052_CR14","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1136\/bmj.291.6507.1457","volume":"291","author":"AR Watson","year":"1985","unstructured":"Watson AR, Rance CP, Bain J (1985) Long term effects of cyclophosphamide on testicular function. Br Med J (Clin Res Ed) 291:1457\u20131460. https:\/\/doi.org\/10.1136\/bmj.291.6507.1457","journal-title":"Br Med J (Clin Res Ed)"},{"key":"5052_CR15","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/j.1365-2125.1996.tb00153.x","volume":"41","author":"SM Yule","year":"1996","unstructured":"Yule SM, Boddy AV, Cole M, Price L, Wyllie R, Tasso MJ, Pearson AD, Idle JR (1996) Cyclophosphamide pharmacokinetics in children. Br J Clin Pharmacol 41:13\u201319. https:\/\/doi.org\/10.1111\/j.1365-2125.1996.tb00153.x","journal-title":"Br J Clin Pharmacol"},{"key":"5052_CR16","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1007\/s00467-010-1717-5","volume":"26","author":"M Van Husen","year":"2011","unstructured":"Van Husen M, Kemper MJ (2011) New therapies in steroid-sensitive and steroid-resistant idiopathic nephrotic syndrome. Pediatr Nephrol 26:881\u2013892. https:\/\/doi.org\/10.1007\/s00467-010-1717-5","journal-title":"Pediatr Nephrol"},{"key":"5052_CR17","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1007\/s00467-003-1170-9","volume":"18","author":"U Vester","year":"2003","unstructured":"Vester U, Kranz B, Zimmermann S, Hoyer P (2003) Cyclophosphamide in steroid-sensitive nephrotic syndrome: outcome and outlook. Pediatr Nephrol 18:661\u2013664. https:\/\/doi.org\/10.1007\/s00467-003-1170-9","journal-title":"Pediatr Nephrol"},{"key":"5052_CR18","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1136\/adc.65.10.1147","volume":"65","author":"N Ueda","year":"1990","unstructured":"Ueda N, Kuno K, Ito S (1990) Eight and 12 week courses of cyclophosphamide in nephrotic syndrome. Arch Dis Child 65:1147\u20131150. https:\/\/doi.org\/10.1136\/adc.65.10.1147","journal-title":"Arch Dis Child"},{"key":"5052_CR19","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1007\/s00467-004-1759-7","volume":"20","author":"U Vester","year":"2005","unstructured":"Vester U, Kranz B, Zimmermann S, B\u00fcscher R, Hoyer PF (2005) The response to cyclophosphamide in steroid-sensitive nephrotic syndrome is influenced by polymorphic expression of glutathion-S-transferases-M1 and -P1. Pediatr Nephrol 20:478\u2013481. https:\/\/doi.org\/10.1007\/s00467-004-1759-7","journal-title":"Pediatr Nephrol"},{"key":"5052_CR20","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1007\/s00467-006-0276-2","volume":"21","author":"R Bhimma","year":"2006","unstructured":"Bhimma R, Adhikari M, Asharam K (2006) Steroid-resistant nephrotic syndrome: the influence of race on cyclophosphamide sensitivity. Pediatr Nephrol 21:1847\u20131853. https:\/\/doi.org\/10.1007\/s00467-006-0276-2","journal-title":"Pediatr Nephrol"},{"key":"5052_CR21","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1007\/s00467-011-1825-x","volume":"26","author":"A Zagury","year":"2011","unstructured":"Zagury A, de Oliveira AL, de Moraes CA, de Araujo Montalv\u00e3o JA, Novaes RH, de S\u00e1 VM, Monteiro de Carvalho Dde B, Matuck T (2011) Long-term follow-up after cyclophosphamide therapy in steroid-dependent nephrotic syndrome. Pediatr Nephrol 26:915\u2013920. https:\/\/doi.org\/10.1007\/s00467-011-1825-x","journal-title":"Pediatr Nephrol"},{"key":"5052_CR22","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1046\/j.1523-1755.2001.0590051919.x","volume":"59","author":"A Durkan","year":"2001","unstructured":"Durkan A, Hodson E, Willis N, Craig J (2001) Immunosuppressive agents in childhood nephrotic syndrome: a meta-analysis of randomized controlled trials. Kidney Int 59:1919\u20131927. https:\/\/doi.org\/10.1046\/j.1523-1755.2001.0590051919.x","journal-title":"Kidney Int"},{"key":"5052_CR23","doi-asserted-by":"publisher","first-page":"CD002290","DOI":"10.1002\/14651858.CD002290.pub5","volume":"4","author":"NG Larkins","year":"2020","unstructured":"Larkins NG, Liu ID, Willis NS, Craig JC, Hodson EM (2020) Non-corticosteroid immunosuppressive medications for steroid-sensitive nephrotic syndrome in children. Cochrane Database Syst Rev 4:CD002290. https:\/\/doi.org\/10.1002\/14651858.CD002290.pub5","journal-title":"Cochrane Database Syst Rev"},{"key":"5052_CR24","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1007\/pl00013435","volume":"14","author":"MJ Kemper","year":"2000","unstructured":"Kemper MJ, Altrogge H, Ludwig K, Timmermann K, M\u00fcller-Wiefel DE (2000) Unfavorable response to cyclophosphamide in steroid-dependent nephrotic syndrome. Pediatr Nephrol 14:772\u2013775. https:\/\/doi.org\/10.1007\/pl00013435","journal-title":"Pediatr Nephrol"},{"key":"5052_CR25","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1136\/adc.62.11.1102","volume":"62","author":"Report of Arbeitsgemeinschaft f\u00fcr P\u00e4diatrische Nephrologie","year":"1987","unstructured":"Report of Arbeitsgemeinschaft f\u00fcr P\u00e4diatrische Nephrologie (1987) Cyclophosphamide treatment of steroid dependent nephrotic syndrome: comparison of eight week with 12 week course. Arch Dis Child 62:1102\u20131106. https:\/\/doi.org\/10.1136\/adc.62.11.1102","journal-title":"Arch Dis Child"},{"key":"5052_CR26","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1007\/s00467-020-04570-y","volume":"35","author":"JA Kari","year":"2020","unstructured":"Kari JA, Alhasan KA, Albanna AS, Safdar OY, Shalaby MA, B\u00f6ckenhauer D, El-Desoky SM (2020) Rituximab versus cyclophosphamide as first steroid-sparing agent in childhood frequently relapsing and steroid-dependent nephrotic syndrome. Pediatr Nephrol 35:1445\u20131453. https:\/\/doi.org\/10.1007\/s00467-020-04570-y","journal-title":"Pediatr Nephrol"},{"key":"5052_CR27","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s00467-015-3245-9","volume":"31","author":"H Webb","year":"2016","unstructured":"Webb H, Jaureguiberry G, Dufek S, Tullus K, Bockenhauer D (2016) Cyclophosphamide and rituximab in frequently relapsing\/steroid-dependent nephrotic syndrome. Pediatr Nephrol 31:589\u2013594. https:\/\/doi.org\/10.1007\/s00467-015-3245-9","journal-title":"Pediatr Nephrol"},{"key":"5052_CR28","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/ki.2014.354","volume":"87","author":"PF Hoyer","year":"2015","unstructured":"Hoyer PF (2015) New lessons from randomized trials in steroid-sensitive nephrotic syndrome: clear evidence against long steroid therapy. Kidney Int 87:17\u201319. https:\/\/doi.org\/10.1038\/ki.2014.354","journal-title":"Kidney Int"},{"key":"5052_CR29","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1681\/ASN.2005090922","volume":"17","author":"PF Hoyer","year":"2006","unstructured":"Hoyer PF, Brodeh J (2006) Initial treatment of idiopathic nephrotic syndrome in children: prednisone versus prednisone plus cyclosporine A: a prospective, randomized trial. J Am Soc Nephrol 17:1151\u20131157. https:\/\/doi.org\/10.1681\/ASN.2005090922","journal-title":"J Am Soc Nephrol"},{"key":"5052_CR30","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s004670000523","volume":"16","author":"K Latta","year":"2001","unstructured":"Latta K, von Schnakenburg C, Ehrich J (2001) A meta-analysis of cytotoxic treatment for frequently relapsing nephrotic syndrome in children. Pediatr Nephrol 16:271\u2013282. https:\/\/doi.org\/10.1007\/s004670000523","journal-title":"Pediatr Nephrol"},{"key":"5052_CR31","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/s0272-6386(87)80087-2","volume":"9","author":"JS Berns","year":"1987","unstructured":"Berns JS, Gaudio KM, Krassner LS, Anderson FP, Durante D, McDonald BM, Siegel NJ (1987) Steroid-responsive nephrotic syndrome of childhood: a long-term study of clinical course, histopathology, efficacy of cyclophosphamide therapy, and effects on growth. Am J Kidney Dis 9:108\u2013114. https:\/\/doi.org\/10.1016\/s0272-6386(87)80087-2","journal-title":"Am J Kidney Dis"},{"key":"5052_CR32","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.12669\/pjms.36.6.2337","volume":"36","author":"KN Moorani","year":"2020","unstructured":"Moorani KN, Zubair AM, Veerwani NR, Hotchandani HJ (2020) Efficacy of levamisole in children with frequent relapsing and steroid dependent nephrotic syndrome at tertiary care center-Karachi. Pak J Med Sci 36:1193\u20131198. https:\/\/doi.org\/10.12669\/pjms.36.6.2337","journal-title":"Pak J Med Sci"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-021-05052-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-021-05052-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-021-05052-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,17]],"date-time":"2021-08-17T10:11:37Z","timestamp":1629195097000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00467-021-05052-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,31]]},"references-count":32,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["5052"],"URL":"https:\/\/doi.org\/10.1007\/s00467-021-05052-5","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,31]]},"assertion":[{"value":"17 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Institutional ethics committee.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical clearance"}}]}}